ClinicalTrials.gg

Clear-cell metastatic renal cell carcinoma clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 70 studies for Clear-cell metastatic renal cell carcinoma across more than 10 countries. 31 are recruiting or about to start. 57 of them are mainly about Clear-cell metastatic renal cell carcinoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

Status

Recruiting
25
Completed
20
Terminated
10
Active, not recruiting
5
Not yet recruiting
5
Withdrawn
3

Phase

Phase 2
40
Phase 1
26
Phase 3
4
Early Phase 1
3
Phase 4
2

Where

United States
38
France
12
Canada
8
China
8
Spain
6
Italy
6

Who develops what

Add Clear-cell metastatic renal cell carcinoma to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 5 companies, 5 with this as their studies’ main aim; 1 with a live phase 3 study; 2 primary completions in the next 12 months. Compare Beijing Biotech, Arcus Biosciences and Bristol-Myers Squibb here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
cabozantinibRecent, limited
Evidence
  • NCT07011719 · Arcus Biosciences, Inc. · Phase 3 · live · background · “Cabozantinib” · registered Jun 2025
Exelixis64% of its industry studiesUS: Exelixis (FDA 2012)EU: Ipsen (EMA 2014)11 study
IpilimumabRecent, limited
Evidence
  • NCT07227415 · Pfizer · Phase 2 · live · background · “Ipilimumab” · registered Nov 2025
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)11 study
casdatifanRecent, limited
Evidence
  • NCT07227415 · Pfizer · Phase 2 · live · background · “Casdatifan” · registered Nov 2025
Arcus Biosciences, Inc.78% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
casdatifan☆ Track1 live phase-3 study: NCT07011719Arcus Biosciences, Inc.

The 1 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 14 Apr 2027 est.eb-701, EB-701/CA9-NK, fludarabine · Beijing Biotech · Phase 2 main aimNCT07551349 Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma — primary endpoint: Incidence of dose-limiting toxicities (DLTs) · 36 enrolled
  • 2 Nov 2027 est.tivunatamig · Pfizer · Phase 2 main aimstudied with Ipilimumabstudied with casdatifanNCT07227415 Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — primary endpoint: Confirmed objective response rate (ORR) using RECIST v1.1 as assessed by investigator · 224 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Clear-cell metastatic renal cell carcinoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 5 open · Immune checkpoint inhibitors 5 open

Coming up

13studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 25 Clear-cell metastatic renal cell carcinoma studies recruiting now, 22 (88%) set no upper age limit and 1 (4%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 25
AgeWomenMen
100 (0%)0 (0%)
1825 (100%)25 (100%)
3025 (100%)25 (100%)
4025 (100%)25 (100%)
5025 (100%)25 (100%)
6525 (100%)25 (100%)
7525 (100%)25 (100%)
8524 (96%)24 (96%)

Across all 70 studies, recruiting or not: 7% stop at 75 or younger and 0% at 65; 1% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 20, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 70. Browse all 70 → or search them.